Search

everythinglearnresearchcommunity

for

Search:↓

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Janus kinase inhibitors show promise for treating alopecia areata in children.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.

Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Alopecia areata severity is linked to increased TH1 and TH2 activity.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.

Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

Cytotoxic T cells cause hair loss in chronic alopecia areata.

Alopecia areata involves specific gene changes and immune pathways, offering new treatment targets.

Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

People with alopecia areata may have a higher risk of blood clots.

Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.

Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.

Wnt/beta-catenin signaling in the skin helps fat cell development during hair growth and repair.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.

Regulatory T cells are essential for normal and improved wound healing in mice.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

Leptin affects skin and hair health and may worsen some skin conditions, but more research is needed to understand its full impact.

Fetal-maternal stem cells in a mother's hair can help with tissue repair and regeneration long after childbirth.